Statement Regarding Media Report
Key facts
- Statement Regarding Media Report
- PharmaEssentia Corp. clarifies that financial forecasts reported by the China Times Business News are not official statements but third-party estimates, urging investors to refer to official disclosures.
- Source: PR Times
- Date: June 19, 2026
Direct answer
PharmaEssentia Corp. clarifies that financial forecasts reported by the China Times Business News are not official statements but third-party estimates, urging investors to refer to official disclosures.
- Citation
- Statement Regarding Media Report (June 19, 2026), PR Times
- Source
- PR Times
- Date
- June 19, 2026
PharmaEssentia Corp. clarifies that financial forecasts reported by the China Times Business News are not official statements but third-party estimates, urging investors to refer to official disclosures.
📋 Article Processing Timeline
- 📰 Published: June 19, 2026 at 09:00
- 🔍 Collected: June 19, 2026 at 06:28
- 🤖 AI Analyzed: June 19, 2026 at 13:32 (7h 4m after Collected)
Disclosure Date: June 19, 115
Statement Date: June 18, 115
Statement Time: 11:17:37
Company Code: 6446
Company Name: PharmaEssentia Corp.
Subject: Clarification on Media Report
Applicable Clause: Clause 51
Factual Date: June 18, 115
Explanation:
1. Factual Date: June 18, 115
2. Company Name: PharmaEssentia Corporation
3. Relationship with Company: Parent Company
4. Cross-shareholding Ratio: Not applicable
5. Media Outlet: China Times Business News
6. Report Content: On June 18, 115, China Times Business News reported: "Analysts project annual revenue could surpass NT$20 billion, setting a new record, with profits exceeding NT$2 per share, potentially making the company the most profitable in the biotech sector."
7. Reason for Disclosure: Response to media report
8. Countermeasures: The company has not released any predictive financial or business information. The financial forecasts regarding the company published by China Times Business News are purely media and analyst estimates. Investors should refer to disclosures on the "Public Information Observation Station" for accurate financial and business updates.
9. Other Matters: New drug development involves long timelines, high investment costs, and no guarantee of success, posing potential investment risks. Investors are advised to make cautious judgments and invest prudently.
Statement Date: June 18, 115
Statement Time: 11:17:37
Company Code: 6446
Company Name: PharmaEssentia Corp.
Subject: Clarification on Media Report
Applicable Clause: Clause 51
Factual Date: June 18, 115
Explanation:
1. Factual Date: June 18, 115
2. Company Name: PharmaEssentia Corporation
3. Relationship with Company: Parent Company
4. Cross-shareholding Ratio: Not applicable
5. Media Outlet: China Times Business News
6. Report Content: On June 18, 115, China Times Business News reported: "Analysts project annual revenue could surpass NT$20 billion, setting a new record, with profits exceeding NT$2 per share, potentially making the company the most profitable in the biotech sector."
7. Reason for Disclosure: Response to media report
8. Countermeasures: The company has not released any predictive financial or business information. The financial forecasts regarding the company published by China Times Business News are purely media and analyst estimates. Investors should refer to disclosures on the "Public Information Observation Station" for accurate financial and business updates.
9. Other Matters: New drug development involves long timelines, high investment costs, and no guarantee of success, posing potential investment risks. Investors are advised to make cautious judgments and invest prudently.
FAQ
Is PharmaEssentia's revenue forecast accurate?
No, the company has not issued any official forecast. The report is based on media speculation.
Where can I find accurate information?
Refer to the 'Public Information Observation Station' for official and verified disclosures.
What are the risks in drug development?
Drug development is costly, time-consuming, and carries no guarantee of success.